publication date: Oct. 20, 2017

Sharpless sworn in as 15th NCI director

Norman “Ned” Sharpless Oct. 17 was sworn in as the 15th NCI director, succeeding Harold Varmus, who stepped down as director in March 2015, and Douglas Lowy, who has served as acting director since that time.

Sharpless is the former director of the University of North Carolina Lineberger Comprehensive Cancer Center and the Wellcome Distinguished Professor in Cancer Research. As an oncologist, he specialized in hematologic malignancies.

Lowy has resumed his role as a deputy director at NCI, and will continue his work as chief of the Laboratory of Cellular Oncology in NCI’s Center for Cancer Research.

In an email addressed to “NCI Colleagues,” Sharpless wrote:

Yesterday I had the distinct honor of being sworn in as the 15th Director of the National Cancer Institute and am delighted to be writing to you for the first time in this role.

As a scientist focusing on how aging causes cancer, as a clinical oncologist caring for patients with leukemia, and as director of the NCI-designated UNC Lineberger Comprehensive Cancer Center, my career has been connected to NCI in many ways. I am honored and humbled to now assume a leadership role at the world’s premier cancer research institution.

It is particularly exciting to have the opportunity to lead in this critical moment, when the discoveries and tools developed in recent decades allow us to tailor cancer prevention, detection, and treatment. Also, we have a great opportunity to face even the most daunting cancers with innovation and accelerated development of novel interventions.   

In the weeks ahead, I look forward to meeting many of you and hearing about your ideas and your challenges as I … Continue reading Sharpless sworn in as 15th NCI director

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.